Journal Information
Vol. 6. Issue 5.
Pages 478-489 (September - October 2000)
Share
Share
Download PDF
More article options
Vol. 6. Issue 5.
Pages 478-489 (September - October 2000)
Open Access
Antibióticos em doentes neutropénicos*
Visits
4250
Rui Sarmento E. Castro**,***
** Assistente Graduado de Infecciologio do Hospital de Joaquim Urbano. Porto
This item has received

Under a Creative Commons license
Article information
RESUMO

A avaliação clínica e diagnóstica de doentes neutropénicos com febre é, frequenternente, complexa. As infecções nestes doentes podem ser particularmente graves, exigindo o início rápido de terapêutica antibiótica de largo espectro por via endovenosa. O regime terapêutico mais usado é o constituído pela associação de aminoglicosídeos com cefalosporinas ou penicilinas com actividade anti-pseudomonas, embora em casos menos graves possa usarse apenas um antibiótico (em geral ceftazidima ou imipenem/cilastatina). A associação de vancomicina ao esquema inicial, não aconselhada por rotina, pode ter indicação sobretudo quando se presume infecção grave por gram positivos. A duração da terapêutica deve ser determinada em função da evolução clínica e da contagem de neutrófilos.

ABSTRACT

Clinical and diagnostic evaluation of neutropenic patients with fever is frequently difficult. Infection in these patients may be serious and rapidly fatal demanding urgent use of broad-spectrum bactericidal antibiotics by intravenous route. The most commonly used scheme is the association of an aminoglycoside with a third-generation cephalosporin or an antipseudomonal penicillin, although in low-risk patients monotherapy can be used (ceflazidime or imipenem/cilastatin). The routine use of vancomycin as part of the initial therapy is not recommended, unless serious gram positive infection is presumed. The most important determinants of the duration of therapy are the patient’s clinical condition and neutrophil count.

Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
P.A. Pizzo.
Fever in immunocompromised patients.
N Engl J Med, 341 (1999), pp. 893-899
[2.]
A.G. Freifeld, T.J. Walsh, P.A. Pizzo.
Infections in the cancer patient.
Cancer: principles and practice of oncology, 5th ed, pp. 2659-2704
[3.]
M. Weinberger, I. Elattar, D. Marshall, et al.
Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death.
Medicine Baltimore, 71 (1992), pp. 24-43
[4.]
G.P. Bodey, M. Buckley, Y.S. Sathe, et al.
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
Ann Intern Med, 64 (1966), pp. 328-340
[5.]
S.C. Schimpff.
Empiric antibiotic therapy for granulocy topenic cancer patients.
Am J Med, 80 (1986), pp. 13-20
[6.]
K.G. Lucas, A.E. Brown, D. Armstrong, et al.
The indentilication of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis.
Cancer, 77 (1996), pp. 791-798
[7.]
D.C. Dale, D. Guerry 4th, J.R. Wewerka, et al.
Chronic neutropenia.
Medicine Baltimore, 58 (1979), pp. 128-144
[8.]
F. Meunier.
Infections in patients with acute leukemia and lymphoma.
Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, 4th ed, pp. 2675-2686
[9.]
J.O. Armitage.
Treatment of non-Hodgkin’s lymphoma.
N Engl J Med, 328 (1993), pp. 1023-1030
[10.]
W.T. Hughes, D. Armstrong, G.P. Bodey, et al.
1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.
Clin Infect Dis, 25 (1997), pp. 551-573
[11.]
EORTC International Antimicrobial Therapy Cooperative Group.
Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.
N Engl J Med, 317 (1987), pp. 1692-1698
[12.]
P.M. Flynn, B. Van Hooser, F. Gigliotti.
Atypical mycobacterial infections of Hickman catheter exit sites.
Pediatr Infect Dis J, 7 (1988), pp. 510-513
[13.]
U. Allen, C.R. Smith, C.G. Prober.
The value of skin biopsies in febrile, neutropenic, immunocompromised children.
Am J Dis Child, 140 (1986), pp. 459-461
[14.]
J.M. Conly, K. Ramotar, H. Chubb, et al.
Hypoprothrombinemia in febrile, neutropenic patients with cancer: association with antimicrobial suppression of intestinal microflora.
J Infect Dis, 150 (1984), pp. 202-212
[15.]
V. Fainstein, G.P. Bodey, K.B. Mccredie, et al.
Coagulation abnormalities induced by B-lactam antibiotics in cancer patients.
J Infect Dis, 148 (1983), pp. 745-750
[16.]
P.-Y. Bochud, T. Calandra, P. Francioli.
Bacteremia due to viridans streptococci in neutropenic patients: a review.
Am J Med, 97 (1994), pp. 256-264
[17.]
O.W. Press, P.G. Ramsey, E.B. Larson, et al.
Hickman catheter infections in patients with malignancies.
Medicine Ballimore, 63 (1984), pp. 189-200
[18.]
D. Benezra, T.E. Kiehn, J.W.M. Gold, et al.
Prospective study of infections in indwelling central venous catheters using quantitative blood cultures.
Am J Med, 85 (1988), pp. 495-498
[19.]
I.I. Raad, S. Vartivarian, A. Khan, et al.
Catheter related infections caused by the Mycobacterium fortuirum complex: 15 cases and review.
Rev infect Dis, 13 (1991), pp. 1120-1125
[20.]
E.A. Blumberg, A.C. Reboli.
Failure of systemic empirical treatment with amphotericin B to prevent eandidemia in neutropenic patients with cancer.
Clin Infect Dis, 22 (1996), pp. 462-466
[21.]
O.J. Winston, W.G. Ho, D.A. Bruckner, et al.
Betalactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazonc plus piperacillin, ccftazidimc plus piperacillin, and imipenem alone.
Ann Intern Med, 115 (1991), pp. 849-859
[22.]
M.J. Leyland, K.F. Bayston, J. Cohen, et al.
A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies.
J Antimicrob Chemother, 30 (1992), pp. 843-854
[23.]
European Organization for Research and Treatment of Cancer (EORTC) lnternational Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - Clinical Trials Group.
Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients.
J Infeet Dis, 163 (1991), pp. 951-958
[24.]
R. Ramphal, B.S. Kramer, K.H. Rand, et al.
Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients.
J Antimicrob Chemother, 12 (1983), pp. 81-88
[25.]
P.A. Pizzo, J.W. Hathorn, J. Hiemenz, et al.
A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.
N Engl J Med, 315 (1986), pp. 552-558
[26.]
J.W. Sanders, N.R. Powe, R.D. Moore.
Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta analysis.
J Infect Dis, 164 (1991), pp. 907-916
[27.]
P.R.E. Johnson, J.A. Liu Yin, J.A. Tooth.
High dose intravenous ciprotloxacin in febrile neutropenic patients.
J Antimicrob Chemother, 26 (1990), pp. 101-107
[28.]
P.R.E. Johnson, J.A. Liu Yin, J.A. Tooth.
A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients.
J Antimicrob Chemother, 30 (1992), pp. 203-214
[29.]
D. Oblon, R. Ramphal.
A randomized trial of cefepime vs ceftazidime as initial therapy for patients with prolonged fever and neutropenia after intensive chemotherapy [abstract].
Proceedings of the Annual Meeting of the American Association for Cancer Research, 34 (1993), pp. 1362
[30.]
H. Kieft, A.I.M. Hoepelman, M. Rozenberg-Arska, et al.
Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome.
Antimicrob Agents Chemother, 38 (1994), pp. 415-421
[31.]
A. Cometta, T. Calandra, A.H. Gay, et al.
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer.
Antimicrob Agents Chemother, 40 (1996), pp. 1108-1115
[32.]
F. Menichetti, P. Martino, G. Bucaneve, et al.
Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies.
GIMEMA Infection Program. Antimicrob Agents Chemother, 38 (1994), pp. 2041-2046
[33.]
A. Freifeld, D. Marchiglani, T. Walsh, et al.
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chcmoterapy.
N Engl J Med, 341 (1999), pp. 305-311
[34.]
W.V. Kern, A. Cometta, R. De Bock, et al.
Oral versus intravenous empirical antimicrobial therapy for fever in patient with granulocytopenia who are receiving cancer chemotherapy.
N Engl J Med, 341 (1999), pp. 312-318
[35.]
J. Klastersky, G. Vamecq, R. Cappel, et al.
Effects of the combination of gentamicin and carbenicillin on the bactericidal activity of serum.
J Infect Dis, 125 (1972), pp. 183-186
[36.]
K.A. Sepkowitz, A.E. Brown, D. Armstrong.
Empirical therapy for febrile, neutropenic patients: persistence of susceptibility of gram-negative bacilli to aminoglycoside antibiotics [letter].
Clin Infect Dis, 19 (1994), pp. 810-811
[37.]
P.A. Pizzo, S. Ladisch, K. Robichaud.
Treatment of gram-positive septicemia in cancer patients.
Cancer, 45 (1980), pp. 206-207
[38.]
P.A. Pizzo, K.J. Robichaud, F.A. Gill, et al.
Duration of empiric antibiotic therapy in granulocytopenic patients with cancer.
Am J Med, 67 (1979), pp. 194-200
[39.]
W.T. Hughes, G. Patterson.
Post-sepsis prophylaxis in cancer patients.
Cancer, 53 (1984), pp. 137-141
[40.]
L. Crane, S. Komskian, A. Sauber, et al.
Antibiotic therapy in febrile neutropenic patients; what is the optimum duration of therapy? [abstract no 18.
Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy (Los Angeles),
[41.]
J.H. Joshi, S.C. Schimpff, J.H. Tenney, et al.
Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer·patients?.
Am J Med, 76 (1984), pp. 450-457
[42.]
G.H. Talbot, M. Provencher, P.A. Cassileth.
Persistent fever after recovery from granulocytopenia in acute leukemia.
Arch Intern Med, 148 (1988), pp. 129-135
[43.]
D.L. Bartley, W.T. Hughes, L.S. Parvey, et al.
Computed tomography of hepatic and splenic fungal abscesses in leukemic children.
Pedaiatr Infect Dis, 1 (1982), pp. 317-321
[44.]
P.M. Flynn, J.L. Shenep, R. Crawford, et al.
Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients.
Clin Infect Dis, 20 (1995), pp. 964-970
[45.]
S. Bhatia, J. McCullough, E.H. Perry, et al.
Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation.
Transfusion, 34 (1994), pp. 226-232
[46.]
P. Rikonen, U.M. Saarinen, A. Makipernaa, et al.
Recombinant human granulocyte-macrophage colonystimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children.
Pediatr Infect Dis J, 13 (1994), pp. 197-202
[47.]
E.J. Anaissie, S. Vartivarjan, G.P. Bodey, et al.
Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia.
Am J Med, 100 (1996), pp. 17-23
[48.]
D.F. Pon, S.W. Lim, R.M. Look, et al.
Lack of clinically significant fall of white blood cell count (WBC) after early cessation of hematopoietic growth factors for chemotherapy induced neutropenia [abstract no A705].
Proceedings of the Annual Meeting of the Society of Clinical Oncology, 14 (1995),
[49.]
E. Vellenga, C.A. Uyl-De Groot, R. De Wif, et al.
Randomized placebo-controlled trial of granulocyte macrophage colony-stimulating factor in patients with chemotherapy related febrile neutropenia.
J Clin Oncol, 14 (1996), pp. 619-627
[50.]
W.T. Hughes, G.K. Rivera, M.J. Sebell, et al.
Success ful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis.
N Engl J Med, 316 (1987), pp. 1627-1632
[51.]
J. Carratalá, A. Fernández-Sevilla, F. Tubau, et al.
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
Clin Infect Dis, 20 (1995), pp. 557-560
[52.]
N. Somolinos, R. Arranz, M.C. Del Rey, et al.
Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients [letter].
J Anti microb Chemother, 30 (1992), pp. 730-731
[53.]
W.V. Kern, E. Andriof, M. Octhinger, et al.
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.
Antimicrob Agents Chemother, 38 (1994), pp. 681-687
[54.]
A. Cometta, T. Calandra, J. Bille, et al.
Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia [letter].
N Engl J Med, 330 (1994), pp. 1240-1241

Tema apresentado na Mesa-redonda “Antibióticos e Infecção Respiratória” XV Congresso de Pneumologia, Ofir, 09/11/99

Copyright © 2000. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?